Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations

Podobne knjige/članki

• First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
  od: Holleman, Marscha S, et al.
  Izdano: (2019)
• First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
  od: Holleman MS, et al.
  Izdano: (2019-02-01)
• Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
  od: Remziye Zaim, et al.
  Izdano: (2022-06-01)
• Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
  od: OuYang, Pu-Yun, et al.
  Izdano: (2013)
• Plasma EGFR mutation abundance affects clinical response to first-line EGFR-TKIs in patients with advanced non-small cell lung cancer
  od: Wang, Xiaohong, et al.
  Izdano: (2021)